Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety

被引：13

作者：

Reggia, Rossella ^{[1
,2
]}

Franceschini, Franco ^{[1
,2
]}

Tincani, Angela ^{[1
,2
]}

Cavazzana, Ilaria ^{[1
,2
]}

机构：

[1] Spedali Civil Brescia, Rheumatol & Clin Immunol Dept, I-25125 Brescia, Italy

[2] Univ Brescia, Brescia, Italy

来源：

JOURNAL OF RHEUMATOLOGY | 2015年 / 42卷 / 02期

关键词：

RHEUMATOID ARTHRITIS; THERAPY; ABATACEPT; SUBCUTANEOUS FORMULATION; EFFICACY; SAFETY; ACTIVE RHEUMATOID-ARTHRITIS; LONG-TERM SAFETY; PHASE IIIB; INADEQUATE RESPONSE; TRIAL; METHOTREXATE;

D O I：

10.3899/jrheum.141042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis. Methods. Fifty-one patients treated with SC ABA were included. Clinical data were obtained from clinical charts. Results. Fourteen patients relapsed and needed to return to the IV administration. Neither clinical and laboratory features nor the previous therapies were identified as risk factors for SC formulation inefficacy. Disease activity decreased after the return to IV infusions. Conclusion. SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.

引用

页码：193 / 195

页数：3

共 13 条

[1] Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment [J].

Alten, Rieke ;

Kaine, Jeffrey ;

Keystone, Edward ;

Nash, Peter ;

Delaet, Ingrid ;

Genovese, Mark C. .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (08) :1987-1997

[2] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[3] Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate [J].

Genovese, M. C. ;

Covarrubias, A. ;

Leon, G. ;

Mysler, E. ;

Keiserman, M. ;

Valente, R. ;

Nash, P. ;

Simon-Campos, J. A. ;

Porawska, W. ;

Box, J. ;

Legerton, C., III ;

Nasonov, E. ;

Durez, P. ;

Aranda, R. ;

Pappu, R. ;

Delaet, I. ;

Teng, J. ;

Alten, R. .

ARTHRITIS AND RHEUMATISM, 2011, 63 (10) :2854-2864

[4] Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial [J].

Genovese, Mark C. ;

Pacheco Tena, Cesar ;

Covarrubias, Arturo ;

Leon, Gustavo ;

Mysler, Eduardo ;

Keiserman, Mauro ;

Valente, Robert ;

Nash, Peter ;

Abraham Simon-Campos, J. ;

Box, Jane ;

Legerton, Clarence William, III ;

Nasonov, Evgeny ;

Durez, Patrick ;

Delaet, Ingrid ;

Teng, Julie ;

Alten, Rieke .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (04) :629-639

[5] Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study) [J].

Kaine, Jeffrey ;

Gladstein, Geoffrey ;

Strusberg, Ingrid ;

Robles, Manuel ;

Louw, Ingrid ;

Gujrathi, Sheila ;

Pappu, Ramesh ;

Delaet, Ingrid ;

Pans, Miranda ;

Ludivico, Charles .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (01) :38-44

[6] Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study [J].

Keystone, Edward Clark ;

Kremer, Joel M. ;

Russell, Anthony ;

Box, Jane ;

Abud-Mendoza, Carlos ;

Garza Elizondo, Mario ;

Luo, Allison ;

Aranda, Richard ;

Delaet, Ingrid ;

Swanink, Rene ;

Gujrathi, Sheila ;

Luggen, Michael .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (06) :857-861

[7] Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis - A randomized trial [J].

Kremer, Joel M. ;

Genant, Harry K. ;

Moreland, Larry W. ;

Russell, Anthony S. ;

Emery, Paul ;

Abud-Mendoza, Carlos ;

Szechinski, Jacek ;

Li, Tracy ;

Ge, Zhiyu ;

Becker, Jean-Claude ;

Westhovens, Rene .

ANNALS OF INTERNAL MEDICINE, 2006, 144 (12) :865-876

[8] Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial [J].

Kremer, Joel M. ;

Russell, Anthony S. ;

Emery, Paul ;

Abud-Mendoza, Carlos ;

Szechinski, Jacek ;

Westhovens, Rene ;

Li, Tracy ;

Zhou, Xianhuang ;

Becker, Jean-Claude ;

Aranda, Richard ;

Peterfy, Charles ;

Genant, Harry K. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (10) :1826-1830

[9] Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study [J].

Nash, Peter ;

Nayiager, Sauithree ;

Genovese, Mark C. ;

Kivitz, Alan J. ;

Oelke, Kurt ;

Ludivico, Charles ;

Palmer, William ;

Rodriguez, Cristian ;

Delaet, Ingrid ;

Elegbe, Ayanbola ;

Corbo, Michael .

ARTHRITIS CARE & RESEARCH, 2013, 65 (05) :718-728

[10] Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis [J].

Rakieh, Chadi ;

Conaghan, Philip G. .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 :313-320

← 1 2 →